Nexiguran ziclumeran, an innovative CRISPR-Cas9 gene-editing therapy, demonstrates rapid, sustained suppression of transthyretin (TTR) in hereditary ATTR polyneuropathy patients, showing promising late-phase clinical safety and efficacy.